1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  6. QuickLinks
  1. Launch
  1. My Preqin
Book a demo

Oncodesign Services

Have updates for this profile?  Please contribute data

About Deals Employee data
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

1995

Location

France

Primary Industry

Biotechnology

About

Based in Dijon, France, and founded in 1995 by its CEO Dr. Philippe Genne, Oncodesign Société Anonyme operates as a biopharmaceutical company that conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. In June 2022, Edmond de Rothschild Private Equity (France) along with the company's management acquired a 61.58% majority stake in Oncodesign Services for USD 14.41 per share. As of October 2022, the company is listed on Euronext Growth Market with the ticker symbol ALONC.PA. Oncodesign Société Anonyme offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; Immuno analysis and monitoring, and microbiological monitoring activities. In addition, the company engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company has generated total revenue of EUR 31.3M in the fiscal year 2021. Following the acquisition, the company plans to support its pursuit of organic growth and provide access to other customers or other geographies.
Current Investors
Eurazeo, Edmond de Rothschild Group

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.oncodesign-services.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only

Deals

Deals Type
Buyout
Add-on
LP Direct
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Completed Oncodesign Services 23 Jan 2024
Completed ZoBio BV 23 Jan 2024
Completed Oncodesign Services 30 Jun 2022
Displaying 1-3 of 3

Employee Data

Employee Graph

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo